One Case of Peripheral Neuropathy Induced by Telbivudine Tablets

Abstract

CLC Number:

R994.11

LIU Mengxiao, SONG Jie, ZHANG Chuanhui, JIA Shengnan, SHAO Xue, JIN Zhenjin. One Case of Peripheral Neuropathy Induced by Telbivudine Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 381-382.

References

[1] 中华医学会神经病学分会肌电图与临床神经电生理学组,中华医学会神经病学分会神经肌肉病学组.糖尿病周围神经病诊断和治疗共识[J].中华神经科杂志, 2013, 46(11):787-789.
[2] Dispenzieri A.POEMS syndrome: 2014 update on diagnosis,risk-stratification,and management[J]. Am J Hematol,2014,89(2) : 214-223.
[3] Bircan Kayaaslan, Rahmet Guner.Adverse effects of oral antiviral therapy in chronic hepatitis B[J]. World Journal of Hepatology, 2017, 9(5):227-241.
[4] 国家食品药品监督管理局. EMEA警告替比夫定引起周围神经病变的风险[EB/OL].[2008-10-18][2018-08-01].http://www.sda.gov.cr,ⅣS01/CI.,0389/29742.htmL.
[5] 金辉, 周子晔, 王陈翔, 等. 替比夫定引起的严重不良反应分析[J]. 中国现代应用药学, 2018, 35(8):1245-1247.
[6] Fleischer R D,Lok A S.Myopathy and neuropathy associated with nucleos(t) ide analog therapy for hepatitis B[J]. J Hepatol,2009,51(4):787-791.
[7] Pastermask R C, Smith S C, Baireymerz C N, et al.ACC/AHA/NHLB I clinical advisory on the use and safety of statins[J]. Circulation, 2002, 40(3):567-572.
[8] Zhang X S, Jin R, Zhang S B, et al.Clinical features of adverse reactions associated with telbivudine[J]. World J Gastroenterol, 2008, 14(22):3549-3553.
[9] 林巍, 潘陈为, 金玲湘, 等. 替比夫定相关肌病乳酸性酸中毒周围神经病变1例并文献复习[J]. 温州医学院学报, 2012, 42(1):89-90.
[10] 杜宁, 胡瑾华, 王慧芬. 替比夫定导致周围神经病变3例报道[J]. 传染病信息, 2009, 22(4):254-255.
[11] 姚勤伟, 郭雁宾. 替比夫定联合干扰素α治疗慢性乙型肝炎致周围神经病变4例[J]. 中国新药与临床杂志, 2009, 28(5):399-400.
[12] 国家食品药品监督管理局. 诺华制药称替比夫定与干扰素同时使用可导致周围神经病变[EB/OL]. (2008-10-18)[2018-09-01]. http://www.sda.gov.cn/WS01/CL0389/30364.htmL.

[1]	SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
[2]	ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
[3]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[4]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[5]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[6]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[7]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[8]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[9]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[10]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[11]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[12]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[13]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[14]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[15]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.